ACADIA Pharmaceuticals (NASDAQ:ACAD) Receives “Buy” Rating from Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report released on Thursday,Benzinga reports. The firm currently has a $30.00 target price on the biopharmaceutical company’s stock. ACAD has been the subject of several other reports. Wall Street Zen upgraded ACADIA Pharmaceuticals from a […]
Needham & Company LLC reaffirmed their buy rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report released on Thursday,Benzinga reports. The firm currently has a $30.00 target price on the biopharmaceutical company’s stock. ACAD has been the subject of several other reports. Wall Street Zen upgraded ACADIA Pharmaceuticals from a […]
